Kyle Munz

5 days ago | businessandamerica.com | Kyle Munz

US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas will help drive systemwide change, Keller emphasized that clinicians and providers must ultimately define what is truly valuable in health care.

6 days ago | ajmc.com | Kyle Munz |Antoine Keller

US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas will help drive systemwide change, Keller emphasized that clinicians and providers must ultimately define what is truly valuable in health care.

6 days ago | ajmc.com | Kyle Munz |Naim Alkhouri

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for these drugs to influence MASH resolution and benefit those with more severe fibrosis.

6 days ago | businessandamerica.com | Kyle Munz

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for these drugs to influence MASH resolution and benefit those with more severe fibrosis.

1 week ago | ajmc.com | Kyle Munz |Naim Alkhouri

In a previous installment of his interview with The American Journal of Managed Care®, (AJMC®), Naim Alkhouri, MD, FAASLD, DABOM, chief medical officer, chief of transplant hepatology, and director of the Steatotic Liver Program at Arizona Liver Health pointed to one of the primary obstacles impeding progress in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): awareness.